Moving to advance its leadership in developing vaccines for important public health and biodefense needs, Vaxin Inc. today announced that it has entered into a definitive agreement to acquire Immune Targeting Systems (ITS) Ltd. Vaxin is a clinical stage vaccine development company headquartered in Gaithersburg, Maryland. ITS develops novel T-cell vaccines at its operations in the United Kingdom and France. The deal is an all-stock transaction and is subject to customary closing conditions. The combined company will be known as Vaxin Inc.